RhumbLine Advisers’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

RhumbLine Advisers’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65,539	Closed	-$17K	–	4420
2023 Q1	$17K	Buy	65,539 +548	+0.8%	+$495	﹤0.01%	2939
2022 Q4	$77K	Buy	64,991 +11,383	+21%	+$23.9K	﹤0.01%	2921
2022 Q3	$109K	Buy	+53,608	New	+$91K	﹤0.01%	2993

RhumbLine Advisers's PEAR Position: Q2 2023 in Review

RhumbLine Advisers sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 65,539 shares — an estimated $17K sold.

RhumbLine Advisers first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $109K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

RhumbLine Advisers reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
RhumbLine Advisers sold 65,539 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $17K.
RhumbLine Advisers first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
RhumbLine Advisers's Pear Therapeutics, Inc. Class A Common Stock position peaked at $109K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.